DIPROPYL PHENYL(3,4,5-TRIMETHOXYBENZAMIDO)METHYLPHOSPHONATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KFOIZAWOWBSQPV-UHFFFAOYSA-N
Smiles	CCCOP(=O)(OCCC)C(NC(=O)c1cc(OC)c(OC)c(OC)c1)c2ccccc2
InChI	InChI=1S/C23H32NO7P/c1-6-13-30-32(26,31-14-7-2)23(17-11-9-8-10-12-17)24-22(25)18-15-19(27-3)21(29-5)20(16-18)28-4/h8-12,15-16,23H,6-7,13-14H2,1-5H3,(H,24,25)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H32NO7P
Molecular Weight	465.48
AlogP	3.83
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	13.0
Polar Surface Area	102.13
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	32.0

Assay Description	Organism	Bioactivity
Antiviral activity against Tobacco mosaic virus (TMV) pre-treated with compound for 30 min followed by inoculation on left side of Nicotiana tabacum leaves assessed as virus inactivation effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	210.0 ug.mL-1
Antiviral activity against Tobacco mosaic virus (TMV) pre-treated with 62.5 ug/mL compound for 30 min followed by inoculation on left side of Nicotiana tabacum leaves assessed as virus inactivation effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	28.8 %
Antiviral activity against Tobacco mosaic virus (TMV) pre-treated with 125 ug/mL compound for 30 min followed by inoculation on left side of Nicotiana tabacum leaves assessed as virus inactivation effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	30.3 %
Antiviral activity against Tobacco mosaic virus (TMV) pre-treated with 250 ug/mL compound for 30 min followed by inoculation on left side of Nicotiana tabacum leaves assessed as virus inactivation effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	61.0 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculated on whole Nicotiana tabacum leaves followed by smearing with compound solution on left side of leaves assessed as viral infection curative effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	250.1 ug.mL-1
Antiviral activity against Tobacco mosaic virus (TMV) inoculated on whole Nicotiana tabacum leaves followed by smearing with 125 ug/mL compound solution on left side of leaves assessed as viral infection curative effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	40.9 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculated on whole Nicotiana tabacum leaves followed by smearing with 250 ug/mL compound solution on left side of leaves assessed as viral infection curative effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	50.6 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculated on whole Nicotiana tabacum leaves followed by smearing with 500 ug/mL compound solution on left side of leaves assessed as viral infection curative effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	55.0 %
Antiviral activity against Tobacco mosaic virus (TMV) pre-treated with 500 ug/mL compound for 30 min followed by inoculation on left side of Nicotiana tabacum leaves assessed as virus inactivation effect measured 3 to 4 days post viral infection	Tobacco mosaic virus	83.4 %
Antiviral activity against Tobacco mosaic virus (TMV) inoculated on 500 ug/mL compound smeared Nicotiana tabacum leaves assessed as protective effect against viral infection measured 3 to 4 days post viral infection	Tobacco mosaic virus	58.8 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1320338
PubChem	5075120

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).